The Science Behind Biosimilars: Entering a New Era of Biologic Therapy

on behalf of the American College of Rheumatology

doi:10.1002/art.40388

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy

on behalf of the American College of Rheumatology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	334-344
Number of pages	11
Journal	Arthritis and Rheumatology
Volume	70
Issue number	3
DOIs	https://doi.org/10.1002/art.40388
State	Published - Mar 2018

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.1002/art.40388

Cite this

@article{1215c75e19744bfb8d4bbc4af600deaa,

title = "The Science Behind Biosimilars: Entering a New Era of Biologic Therapy",

author = "{on behalf of the American College of Rheumatology} and Bridges, {S. Louis} and White, {Douglas W.} and Worthing, {Angus B.} and Gravallese, {Ellen M.} and O'Dell, {James R.} and Kamala Nola and Jonathan Kay and Cohen, {Stanley B.}",

note = "Funding Information: Dr. Gravallese has received consulting fees from Eli Lilly and Company, Sanofi, and Janssen (less than $10,000 each) and grant support from AbbVie, Eli Lilly and Company, and Pfizer. Dr. O{\textquoteright}Dell has received consulting fees from Medac and Coherus (less than $10,000 each). Dr. Kay has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Biotech, Merck Sharp & Dohme, Pfizer, Roche Laboratories, Samsung Bioepis, and UCB (less than $10,000 each) and from Amgen and Sandoz (more than $10,000 each). Dr. Cohen has received consulting fees from Amgen, Boehringer Ingelheim, Merck, Pfizer, and Sandoz (less than $10,000 each).",

year = "2018",

month = mar,

doi = "10.1002/art.40388",

language = "English (US)",

volume = "70",

pages = "334--344",

journal = "Arthritis and Rheumatology",

issn = "2326-5191",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - The Science Behind Biosimilars

T2 - Entering a New Era of Biologic Therapy

AU - on behalf of the American College of Rheumatology

AU - Bridges, S. Louis

AU - White, Douglas W.

AU - Worthing, Angus B.

AU - Gravallese, Ellen M.

AU - O'Dell, James R.

AU - Nola, Kamala

AU - Kay, Jonathan

AU - Cohen, Stanley B.

N1 - Funding Information: Dr. Gravallese has received consulting fees from Eli Lilly and Company, Sanofi, and Janssen (less than $10,000 each) and grant support from AbbVie, Eli Lilly and Company, and Pfizer. Dr. O’Dell has received consulting fees from Medac and Coherus (less than $10,000 each). Dr. Kay has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Biotech, Merck Sharp & Dohme, Pfizer, Roche Laboratories, Samsung Bioepis, and UCB (less than $10,000 each) and from Amgen and Sandoz (more than $10,000 each). Dr. Cohen has received consulting fees from Amgen, Boehringer Ingelheim, Merck, Pfizer, and Sandoz (less than $10,000 each).

PY - 2018/3

Y1 - 2018/3

UR - http://www.scopus.com/inward/record.url?scp=85041647674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041647674&partnerID=8YFLogxK

U2 - 10.1002/art.40388

DO - 10.1002/art.40388

M3 - Article

C2 - 29411547

AN - SCOPUS:85041647674

VL - 70

SP - 334

EP - 344

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -